

LIST OF FIGURES

Figure No.	Figure Caption	Page No.
2.1	The schematic diagram of the hypothesis for the present thesis work.	13
3.1	Dose response of GCCase inhibition by ambroxol at pH 7	22
3.2	Dose response of GCCase activation by rebamipide at pH 7	22
4.1	The schematic diagram of hypothesis for the validation of GCCase as a target in 6-OHDA-induced model of PD in rats and the effects of sub-acute administration of ambroxol against 6-OHDA toxicity.	28
4.2.	The experimental design of the study for the validation of GCCase as a target in 6-OHDA-induced model of PD in rats and the effects of sub-acute administration of ambroxol against 6-OHDA toxicity.	33
4.3.	Effect of ambroxol on 6-OHDA-induced alterations on the levels of DA (a), DOPAC (b), HVA (c), DOPAC/DA (d), and HVA/DA (e) in striatal tissues of rats at D-28.	46
4.4	Effect of 6-OHDA and treatment with ambroxol on GCCase enzyme activity in striatal (a) and nigral (b) tissues of rats.	49
4.5	Effect of 6-OHDA and treatment with ambroxol on mitochondrial function in terms of MTT reduction in striatal (a) and nigral (b) tissues of rats.	50
4.6	Effect of ambroxol on 6-OHDA-induced changes on α -synuclein concentration in rat nigral tissues at D-28.	51

4.7	Nissl's staining of SNc in rats on D-28. Control (a); Sham (b); 6-OHDA (c); 6-OHDA+Ambroxol (d); 6-OHDA+Selegiline (e); Data of counting cells (f).	53
4.8	Effect of ambroxol on 6-OHDA-induced changes on the protein levels of cytochrome-C, caspase-9 and caspase-3 in rat nigral tissues.	54
4.9	The outcome of specific objective for the validation of GCase as a target in 6-OHDA-induced model of PD in rats and the effects of sub-acute administration of ambroxol against 6-OHDA toxicity.	63
5.1	The schematic diagram of hypothesis for the evaluation of rebamipide in sub-acute doses for its action against 6-OHDA-induced toxicity in rats.	67
5.2	The experimental design of study for the evaluation of rebamipide in sub-acute doses for its action against 6-OHDA-induced toxicity in rats.	71
5.3	Effect of rebamipide on 6-OHDA-induced changes in the levels of DA (a), DOPAC (b), HVA (c), DOPAC/DA (d), and HVA/DA (e) in ipsilateral striatal tissues of rats.	81
5.4	Effect of rebamipide on 6-OHDA-induced alterations in mitochondrial complex-I (a), complex-II (b), complex-IV (c) and complex-V (d) in ipsilateral striatal tissues of rats.	83
5.5	Effect of rebamipide on 6-OHDA-induced increase in mitochondrial LPO activity in ipsilateral striatal tissues of rats.	84
5.6	Effect of rebamipide on 6-OHDA-induced changes on oxygen consumption in different states of mitochondrial respiration (State 2, State 3, State 4, State 5 via complex-I and state 5 via	87

complex-II) (a) and RCR (b) in rat striatal tissues.

- 5.7** Effect of rebamipide on 6-OHDA-induced alterations in GCase enzymatic activity (a) and α -synuclein protein concentration (b) in ipsilateral nigral tissues of rats. **88**
- 5.8** Effect of rebamipide on 6-OHDA-induced alterations in the protein expression of cytochrome-C, caspase-9 and caspase-3 in rat nigral tissues. **89**
- 5.9** The outcome of specific objective for the evaluation of rebamipide in sub-acute doses for its action against 6-OHDA-induced toxicity in rats. **97**
- 6.1** The schematic diagram of hypothesis for the role of Nrf2 activity in rebamipide-mediated changes against 6-OHDA toxicity in rats. **101**
- 6.2** The experimental design of study for the role of Nrf2 activity in rebamipide-mediated changes against 6-OHDA toxicity in rats. **105**
- 6.3** Effect of rebamipide and Nrf2i on 6-OHDA-mediated loss of TH levels in ipsilateral nigral tissues of rats. **115**
- 6.4** Effect of rebamipide and Nrf2i on 6-OHDA-mediated loss of DA (a) and DAT (b) levels in ipsilateral striatal tissues of rats. **116**
- 6.5** Effect of rebamipide and Nrf2i on 6-OHDA-mediated loss of Nrf2 in the nuclear fraction in ipsilateral nigral tissues of rats. **117**
- 6.6** Effect of rebamipide and Nrf2i on 6-OHDA-mediated loss of SOD activity (a), CAT activity (b) and amount of GSH (c) in ipsilateral nigral tissues of rats. **119**
- 6.7** Effect of rebamipide and Nrf2i on 6-OHDA-induced alterations in mitochondrial complex-I activity (a), GCase enzymatic

activity (b) and α -synuclein protein concentration (c) in ipsilateral nigral tissues of rats.

- 6.8** Nissl's staining of SNc in rats. Control (a); Sham (b); 6-OHDA (c); 6OHDA+Selegiline (d); 6-OHDA+R-80 (e); 6-OHDA+Nrf2i (f); 6-OHDA+Nrf2i+R-80 (g); Data of counting cells (h). **123**
- 6.9** The correlation between nuclear Nrf2 and behavior parameters [rotarod retention time (a); apomorphine-induced rotations (b); catalepsy behavior (c); grip strength scores (d); ambulation (e), rearing (f), central squares crossed (g) and grooming (h) during open field test]. **125**
- 6.10** The correlation between nuclear Nrf2 and PD parameters such as mitochondrial complex-I activity (a), SOD activity (b), CAT activity (c), GSH levels (d), GCase activity (e) and α -synuclein concentration (f). **126**
- 6.11** The correlation between nuclear Nrf2 and PD parameters such as TH levels (a), DAT levels (b), number of Nissl-stained neurons in rat nigral tissues (c) and DA levels (d). **127**
- 6.12** The outcome of specific objective for the role of Nrf2 activity in rebamipide-mediated changes against 6-OHDA toxicity in rats. **136**
- 7.1** The schematic diagram of hypothesis for the assessment of the sub-chronic dose of ambroxol for neurorestorative effects against 6-OHDA-induced model of PD in rats. **140**
- 7.2** The experimental design of study for the assessment of the sub-chronic dose of ambroxol for neurorestorative effects against 6-OHDA-induced model of PD in rats. **143**

7.3	Effect of ambroxol on 6-OHDA-induced alterations in beam performance as assessed by latency to begin the task and total time taken to cross the beam in narrow beam walk test in rats.	151
7.4	Effect of ambroxol on 6-OHDA-induced changes in the TH levels in ipsilateral nigral tissues of rats.	151
7.5	Effect of ambroxol on 6-OHDA-induced alterations in mitochondrial complex-I in ipsilateral nigral tissues of rats.	153
7.6	Effect of ambroxol on 6-OHDA-induced alterations in GCase enzymatic activity (a) and α -synuclein protein concentration (b) in ipsilateral nigral tissues of rats.	154
7.7	Effect of Ambroxol on 6-OHDA-induced changes in the DAT levels in ipsilateral striatal tissues of rats.	155
7.8	Nissl's staining of SNc in rats. Control (a); Sham (b); 6-OHDA (c); 6-OHDA+Ambroxol (d); Data of counting cells (e).	156
7.9	The outcome of specific objective for the assessment of the sub-chronic dose of ambroxol for neurorestorative effects against 6-OHDA-induced model of PD in rats.	165
8.1	The schematic diagram of hypothesis for the evaluation of sub-chronic administration of rebamipide for disease-modifying effects against 6-OHDA-induced model of PD in rats.	169
8.2	The experimental design of study for the evaluation of sub-chronic administration of rebamipide for disease-modifying effects against 6-OHDA-induced model of PD in rats.	172
8.3	Effect of rebamipide on 6-OHDA-induced alterations in beam performance as assessed by latency to begin the task and total time taken to cross the beam in narrow beam walk test in rats.	179

8.4	Effect of rebamipide on 6-OHDA-induced changes in the TH levels in ipsilateral nigral tissues of rats.	180
8.5	Effect of rebamipide on 6-OHDA-induced changes in the DAT levels in ipsilateral striatal tissues of rats.	181
8.6	Effect of rebamipide on 6-OHDA-induced alterations in mitochondrial complex-I (a), GCase enzymatic activity (b) and α -synuclein protein concentration (c) in ipsilateral nigral tissues of rats.	183
8.7	Nissl's staining of SNc region of brain in rats. Control (a); Sham (b); 6-OHDA (c); 6-OHDA+R-80 (d); Data of counting cells (e).	184
8.8	The outcome of specific objective for the evaluation of sub-chronic administration of rebamipide for disease-modifying effects against 6-OHDA-induced model of PD in rats.	189
9.1	The schematic diagram of hypothesis for the design, characterization and evaluation of transdermal patches of rebamipide in rodent model of PD.	194
9.2	Experimental Design for the evaluation of transdermal patches of rebamipide in rodent model of PD.	207
9.3	Absorption spectra of rebamipide	209
9.4	Calibration curve of rebamipide	210
9.5	Rebamipide-containing Transdermal Patches. Formulation A (a), Formulation B (b), Formulation C (c) and Formulation D (d).	212
9.6	<i>Ex vivo</i> drug permeation profiles of formulations (rebamipide-loaded transdermal patches) A, B, C and D through rat skin.	216

9.7	FTIR Spectra of pure drug rebamipide (a), and rebamipide-loaded transdermal patch formulation C (b).	217
9.8	SEM images of pure rebamipide (a, b), and rebamipide-loaded transdermal patch formulation C (c, d) at different magnifications.	218
9.9	Effect of rebamipide (oral and transdermal patches) on 6-OHDA-mediated loss of TH and DA levels in ipsilateral nigral and striatal tissues of rats respectively.	223
9.10	Effect of rebamipide (transdermal patches and oral) on 6-OHDA-induced alterations in GCCase enzymatic activity (a) and soluble α -synuclein protein concentration (b) in ipsilateral nigral tissues of rats.	225
9.11	Effect of rebamipide (transdermal patches and oral) on 6-OHDA-mediated loss of DAT levels in ipsilateral striatal tissues of rats.	226
9.12	Nissl's staining of SNc in rats. Control (a); Sham (b); 6-OHDA (c); 6-OHDA+Selegiline (d); 6-OHDA+R-Oral (e); 6-OHDA+R-Patch (f); Data of counting cells (g).	228
9.13	The outcome of specific objective for the design, characterization and evaluation of transdermal patches of rebamipide in rodent model of PD.	234
10.1	The overall outcomes of the thesis work.	237